Javelin submits Dyloject NDA

Javelin Pharmaceuticals Inc. (NYSE-A:JAV) submitted an NDA to FDA for Dyloject diclofenac injection to manage acute moderate to severe pain. Javelin made the submission under section 505(b)(2) of the ...